Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 435 participants.
Also called NCT01059799
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 435 participants
- Sponsor
- Registry
-
NCT01059799
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Hong Kong SAR China, Japan, Malaysia, South Korea, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01059799. Randomized; no masking; primary purpose treatment. Start 2010-02-01 (actual); primary completion 2010-12-16 (actual). Results posted on 2015-11-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
- Acronym
- BEGIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01059799- Content hash
51fff53ae5cd533fe0f9fce07518844f4359178d918909bb96d631a4be39c2d9